It is critical for prostate cancer researchers and clinicians to have access to comprehensive, sensitive and simple-to-use symptom measures that allow them to understand and quantify the subjective patient experience. The purpose of the current review is to provide a comprehensive review, detailed tool descriptions and objectively defined quality criteria to facilitate tool choices for patients with localized prostate cancer. Using a systematic web-based literature search, we found n ¼ 29 prostate symptom measures described in n ¼ 35 validation studies. To be recommended, tools needed to meet four criteria: broad domain coverage, ability to differentiate objective and subjective experience, good internal consistency and validation in at least two populations and/or having achieved two types of validations. Of the 29 tools reviewed, n ¼ 7 meet our criteria for recommendation, and three in particular (the EPIC-26 (Expanded Prostate Cancer Index Composite)-26, PC-QOL (Prostate Cancer-Quality of Life) and the UCLA-PCI (UCLA Prostate Cancer Index)) showed the strongest psychometrics. There is a reasonable number of measures to choose from that meet criteria for good psychometrics.
INTRODUCTION
The prognosis for patients with prostate cancer has steadily improved 1 but treatment success is usually accompanied by late effects. In order to study the effect of treatments on quality of life (QoL) and understand the subjective patient experience, high quality yet simple-to-use symptom measures are needed. This manuscript provides a comprehensive review, describes the tools themselves and the validation work conducted on each scale, offers objectively defined criteria to facilitate tool choices, and lastly, provides criteria-driven recommendations.
Given the mostly good prognoses associated with prostate cancer as such, disease and treatment-related sequelae are an especially important consideration because several equally efficacious treatments (i.e., surgery, external beam radiation, brachytherapy or a combination of these) or watchful waiting are available for the participants to choose from, but are also associated with their own typical toxicity profiles and sequelae. Men who have received radiotherapy frequently report irritating bowel and bladder symptoms at 3 months post treatment which, however, largely subside at 12 months. 2 Conversely, 11 and 35%, respectively, of men who have undergone surgery report substantial urinary incontinence and the need to wear absorptive pads at 12 months, regardless of their age. Additionally, although only one-third of the prostate cancer patients report inadequate erections pretreatment, this problem is nearly universal 3 months after surgery and only improves gradually, especially in men who had received external beam radiotherapy. 2 Furthermore, hormonal treatments, when used as a primary therapy adjunct adversely affect sexual function, mood and include hot flashes and sweats, breast swelling and tenderness, loss of body hair and weight gain. 3 Moreover relevant, but not prostate-specific, are the pain and distress or bother associated with each of these symptoms or domains. 4, 5 Interestingly, there is large variance in the extent that individuals find the same objective symptoms distressing or bothersome. 6 Moreover, physicians often underestimate the extent and severity of the symptoms, their importance and resultant deficits in QoL following treatment. 7, 8 These observations, in turn, challenge tool developers to include both an objective behavioral dimension of symptoms as well as allow for separate measurement of the specific impact that each set of problems has for the patient's QoL.
Self-report is the standard approach to measurement because (a) health-care professionals have no other direct means to access the patients' experience, and (b) patient's decision-making about when to seek help and their judgments about their QoL is driven by perceived symptom presence and symptom interference with daily life.
Generic symptom and QoL measures may be of some use but are considered inferior to the more sensitive measurement of disease-specific changes in symptoms. Furthermore, global QoL measures can obscure important changes in disease symptoms and treatment-related side effects. 6 This review explicitly excludes generic measures of distress and QoL because comprehensive reviews of such measures are already available elsewhere, 6, 9, 10 whereas our literature search did not reveal any published review of prostate cancer symptom scales.
Several prostate cancer-specific assessment instruments have been developed and a limited set of these has already been reviewed in a British technical report. Morris et al. 11 provided detailed information on the reliability and validity for nine different prostate-specific symptom scales; they reviewed QoL and symptom measures in the same report and excluded all nonEnglish measures and publications. In contrast, our more extensive search revealed 29 different symptom measures, did not exclude tools or publications on the basis of language, and used explicit criteria to recommend certain tools for clinical use in patients with localized cancer.
Specifically, we reviewed all obtainable symptom measures, described their domain coverage and reported on their reliability and validity, with the goal of guiding researchers, clinicians and decision-makers in their choice of assessment tool.
METHODS

Study selection
The data extraction and study review process was performed according to the guidelines for systematic reviews of diagnostic tests. 12 We searched PubMed (1947 to October 2011), CINAHL (1982 to October 2011), EMBASE (1980 to October 2011) and PsycINFO (1872 to October 2011) databases for studies in prostate cancer patients by using the following search terms: 'prostate cancer AND measure OR assessment OR instrument OR questionnaire OR validation OR reliability OR validity OR checklist OR psychometrics AND symptoms.' After eliminating duplicate studies, the titles and abstracts of remaining studies were reviewed independently by two authors (KR and IT) ( Figure 1 ). These authors also reviewed the fulllength articles for all studies that were retained. Uncertainty about whether or not studies met the inclusion criteria was resolved by seeking additional input from another author (WL). KR then performed a detailed assessment of the included studies and identified additional validation studies via cross-referencing.
Study inclusion and evaluation criteria
Only studies of instruments labeled as 'validation studies', administered by an interview or standardized self-report, and designed or adapted specifically for prostate cancer patients were included. We included all languages and where necessary consulted native speakers to assure that we correctly classified and interpreted the studies. We did not systematically search for additional publications about translations into other languages and subsequent revalidation for these languages, however, where such data coincidentally appeared in our search, they are mentioned in the section on tool description.
The details offered in Table 1 allow each reader to draw her or his own conclusions about the scales we covered. However, this much detail can also be quite overwhelming, and to maximize the usefulness of this review, we applied a set of four clearly defined criteria to make transparent and replicable judgments about the perceived quality of a given scale.
The first criterion was comprehensiveness of symptom coverage for localized cancer (judged on a two-point scale, based on whether or not the tool addresses at least three key symptom domains). To be comprehensive while being disease-specific, the following domains should be assessed for prostate cancer: urinary function (incontinence most adversely affected by prostatectomy; obstruction/irritation most adversely affected by external beam radiation or brachytherapy), bowel function (most adversely affected by external beam radiation or brachytherapy) and sexual function (affected by all treatments). 6 Hormonal symptoms were not included as a key domain to determine comprehensiveness because it is not a mainstay treatment for patients with localized cancer, and would therefore not be relevant to the great majority of patients.
The remaining three criteria were: (a) recognition of the possibly different subjective experience of the same physical symptom (scored as yes/no), (b) internal consistency (the key index of reliability, scored as poor if o0.70; adequate if 0.70-0.79 and excellent if X0.80), and (c) extent of validation (rated on a 1-3 scale, depending on whether one or more sample had been tested, and/or different validation strategies had been used). Three authors (KR, WL and RP) convened to establish the criteria and operationally define them to guide decision-making. Next, they independently rated each scale using these criteria, and finally reconvened to aggregate their judgments. Any discrepancies were resolved by reconsulting the relevant article.
Reliability
An elementary premise in psychometrics is that a measure cannot be valid if it is not reliable; therefore, reliability is a foundational characteristic. 13 References identified from databases (n= 941) 
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Most studies in this review reported internal consistency (i.e., the extent to which items that are supposed to measure the same construct correlate with the total scale score) as Cronbach's alpha, and scores were usually provided for the full scales and the subscales. Internal consistency is also important because it can be used as a proxy for reading level, a variable that affects clinical usefulness. If the reading level of a measure is too high, respondents will differentially interpret and/ or misunderstand an item, which in turn will reduce internal consistency. Therefore, high internal consistency, which we consider a key criterion, reflects item clarity, which is likely due to a reading level that is appropriate for the population tested.
Test-re-test reliability was also reported where the data were available, as this may indicate whether the measure is sensitive to change, and therefore suitable for longitudinal research.
Validity
Given the purpose and environment in which symptom measures are typically developed, we made the assumption that all symptom measures included in this review would have face validity (meaning that the tool's objective was obvious even to naïve readers) and at least some content validity (given that experts and, frequently, patients themselves had been involved in determining what needed to be measured). In addition to describing domain coverage, we focused on concurrent validity (i.e., correlates with validated instruments that measure related constructs), construct validity (i.e., measures the construct it is supposed to measure) and criterion validity (i.e., correlates with the real-world outcomes). We also report on predictive validity (a type of criterion validity, i.e., predicts future outcomes) when available, given that predictive validity is considered the most useful form of validation. 13 
RESULTS
Thirty-five articles reporting on 29 instruments met inclusion/ exclusion criteria. All identified instruments are self-reported, none had been administered by interview. Owing to our objective inclusion/exclusion criteria, the decision to include or exclude an article produced no disagreements. Detailed descriptions of instruments and validation information are listed in Table 1, in alphabetical order by the name of the measure. Given that some measures have multiple validation studies, we have tried to make this obvious by listing studies investigating the same tool in chronological order, and numbering and labeling them as additional validation studies for a particular measure. Twentyseven measures were designed specifically for use in prostate cancer patients, whereas two were originally developed in nonprostate cancer populations, but subsequently validated for prostate cancer.
Based on criteria made explicit in Table 2 , we decided to recommend those scales that covered (a) all three content domains, namely urinary, sexual, bowel; (b) measured subjective experience of these symptoms; (c) had a mean internal consistency score of X0.70 and (d) had been rated as at least moderately well validated. As is apparent in 34 Clark's Symptom Indexes 14 and the PSSR; 38 among these recommended scales, three stood out as having particularly strong psychometrics, namely EPIC 26, PC-QOL and UCLA-PCI. Table 1 offers an overview of the tools' features, but its standard format cannot do justice to unique characteristics and applications for some of the scales described. For this reason, certain idiosyncratic strengths and weaknesses would remain hidden unless described in a more narrative format. This narrative follows below and is subdivided by population.
Measures relevant for all prostate cancers Nine symptom measures validated in 18 studies have been created for use across all prostate cancer patients, regardless of their stage or treatment received.
The European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Prostate (EORTC 16 and Functional Assessment of Cancer TherapyProstate (FACT-P) 23 are two of the most widely used measures because of the modular approach they use. Both of these measures are designed as cancer-specific modules, they assess health-related QOL, and can be administered along with a QoL questionnaire (EORTC QLQ-C30 and FACT-G, respectively). 50, 51 Although validation efforts have been made with patients from 13 countries for the EORTC QLQ-PR25, the extent of validation is modest with only one subscale, namely urinary function, having been validated. However, it does measure hormonal treatmentrelated symptoms, a domain often neglected by symptom measures. It is available in 34 other languages. Several older versions of the PR25 came up in our literature search, 52 ,53 but they were not included in the current review because they are precursors to the PR25 and are no longer in use. The German prostate-specific module 25 is also designed as a module to accompany the QLQ-C30 to measure outcomes for patients with localized or advanced disease, and has been validated for prostate cancer patients in German speakers.
The FACT-P 23 was designed to aid in the management of prostate cancer for use in clinical trials and clinical practice evaluation, and is available in 50 languages. Whereas conveniently short with only 12 questions, it only allows for a brief overview of symptoms and lacks subscales; its internal consistency is inadequate.
Although we praise the UCLA-PCI 31,47,48 for its many strengths, it has been criticized for its poor coverage of irritative voiding symptoms associated with radiation. 17 The EPIC 17 was originally derived from the UCLA-PCI, with the advantage that it does cover irritative voiding symptoms (urinary and bowel) and items relating Rating based on prostate-specific module only.
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to androgen deprivation. 17 It is available in several versions, including an abbreviated version, 18, 19 and a version designed for clinical use. 20 The longer EPIC-50 17 is necessary whenever it is important to assess function and bother distinctly, which are otherwise collapsed in EPIC-26 and EPIC-CP (EPIC for Clinical Practice). 20 The EPIC-26 was used in a multicenter prospective study of change after primary treatment of early-stage prostate cancer in 1201 men and obtained pre-treatment scores, with means that can be considered norm scores for the various domains. 54 The Patient-Oriented Prostate Utility Scale (PORPUS) [30] [31] [32] covers a large range of symptoms, including some that are more relevant to palliative patients such as pain and energy. Moreover, some domains it covers are not symptom-related (e.g., communication with health-care provider), and therefore may not be useful to some clinicians/researchers. It is unique from other measures covered in this review in that it was originally designed as a 'health utility' scale; as such it would benefit from further validation as a psychometric instrument. Although it has been used as a psychometric instrument, 55 its internal consistency has not been evaluated. It is also available in German. 55 The Estudio sobre la Calidad de Vida en el Cáncer de Pró stataCalidad de Vida 21 includes a wide variety of domains, some of which may be of limited use for those primarily concerned with symptom measurement (e.g., economic status). It is currently only available in Spanish.
Similarly, the European Quality of Life Questionnaire (EQOL) 22 is primarily a QoL instrument and its use as a symptom measure is therefore limited.
Specialized tests/tests for subgroups Some measures specifically assess symptoms that are expected or critical for one specific type of treatment or stage, and are described separately below.
Stage-specific. The following seven measures (validated in eight articles) have been validated only in patients with localized prostate cancer. The Prostate Cancer-Specific Instrument 34 and Clark's Symptom Indexes 14 were both designed for use in earlystage prostate cancer patients, and have been validated across patients receiving various treatments. The PCSI has the added advantage of measuring bother associated with the symptoms, although it is also relatively lengthy and therefore may not be feasible in some settings. 34 It has a vast domain coverage, including topics such as treatment satisfaction and regret, and builds upon previous work. 33 The Late Effects of Normal Tissue (LENT) 27 instrument has only been validated in patients who have received brachytherapy, and would therefore benefit from further validation in other patient populations.
The following measures were designed specifically for use in prostate cancer patients with advanced cancer, which is likely hormone-resistant. Although the primary focus of this review was to investigate questionnaires suitable for patients with localized cancer, these measures are included for those that are also interested in assessing symptoms in patients with advanced cancer. We emphasize that the criteria for comprehensiveness (see Table 2 ) may not be appropriate for measures that are designed for advanced or metastatic cancer, therefore, these results should be interpreted with caution. However, the criteria for measuring subjective experience, reliability and validity are equally applicable here.
Both the QII 40 and the Prostate Cancer-Specific Quality of Life Instrument (PROSQOLI 35, 36 ) are predominantly QoL measures, and provide only cursory coverage of symptoms. The PROSQOLI's objective was to assess the palliative benefit of treatment and was meant to be sensitive to change over time. 35 It is disadvantaged in that most of its questions are on a linear analog scale, making scoring and interpretation of data a challenge. There is also the NCCN/FACT-P Symptom Index-17 29 and the FACT Advanced Prostate Symptom Index-8 (FAPSI). 24 Treatment-specific. The following seven measures (validated in eight articles) were designed or validated for patients receiving particular treatments for prostate cancer.
Two measures were designed for patients who had undergone a prostatectomy. The Prostatectomy Therapy Survey Instruments, 39 while concise and assessing issues most relevant to those who have received surgery (e.g., urinary stricture), was not psychometrically validated. Vickers' STAR 46 demonstrates excellent internal consistency for each scale and was validated in a large sample, and is laudably short. It is comprised of a subset of questions from the PCSI. 34 Five measures have been designed for patients receiving external beam radiotherapy. Dale 15 and Wang's 49 symptom indexes are essentially the same, they are simply worded differently for patients undergoing external beam radiotherapy 14 or those who have completed radiotherapy. 49 Both suffer from the same limitation of not measuring urinary incontinence. Although this symptom is relatively rare in radiotherapy patients, it may still be clinically important to assess. There is also the QUFW94 (later renamed the Prostate Cancer Symptom Scale) 41, 42 the Radiation Adverse Effect QOL tool 43 and the Prostate Symptom Self-Report (PSSR; for those receiving brachytherapy). 38 
DISCUSSION
This is a comprehensive, systematic review of patient-reported symptom measures for use specifically with prostate cancer. Twenty-nine scales were identified that met our inclusion criteria, seven were considered to have sufficiently good psychometrics to permit recommendation for use, and three in particular, EPIC-26, 18, 19 PC-QOL 33 and UCLA-PCI, 31, 47, 48 stood out as the best choices with strong psychometrics and the additional quality of being relatively short. All of the recommended tools were developed within the last 14 years, and many represent revisions and improvements of earlier scales. Moreover, of interest for potential test adopters is that two of the top three rated scales, the UCLA-PCI and the EPIC 26 are known to be free, whereas the cost issue for the PC-QoL could not be readily established. This qualifier notwithstanding, potential users should always write to the copyright holders to obtain permission for use.
Although we set a standard for domains that need to be covered, that does not mean that all the tools tapping all domains also provide equally good coverage of each domain, and even relatively good tools may have room for improvement. For example, sexual difficulties can refer to erection difficulties or loss of desire (or both); they are inter-related but are not the same. 34 Moreover, not usually covered is the useful option of asking a spouse about the impact of symptoms on relationship quality. As well, the literature was mixed in whether tools measured urinary irritation or obstructive symptoms separately from urinary incontinence. Distinguishing between these two types of symptoms is important, because symptom presentation differs greatly depending on the type of treatment patients have received, such that those who have undergone radiotherapy are more likely to experience irritation and/or obstruction, and those who have undergone a prostatectomy will more often suffer from incontinence. Although an excellent scale in most respects, the UCLA-PCI 31, 47, 48 suffers from this limitation. Similarly, incontinence has far-reaching consequences that can be assessed further (e.g., would be to ask for number of pads required per day). Owing to the embarrassing social consequences of incontinence, patients will sometimes socially withdraw, and this behavior can be mistaken for depression. 5 The exclusive focus on symptom measures (which for the most part arise as a result of treatment) in this review need not prevent There is no singular gold standard with which to assess these tools; in each case, choosing a tool requires first to ensure that the chosen tool has been validated for the intended sample and context. In a related fashion, a clinical trial may have a very narrow target and the tools we recommend may still be too insensitive for this purpose, and a new measure (or maybe even a single item) may need to be added. Several weaknesses were apparent across multiple instruments we reviewed. On a number of occasions, we observed that new tools were developed without prior literature review, and then applied to a clinical study with minimal, if any, validation work. Next, some questionnaires contained subscales with an unacceptably low internal consistency, and additional test development work might have reduced or eliminated this problem. Rather than settling for poor reliability, a researcher should determine whether the item is unreliable due to poor wording and patients possibly misinterpreting the question's meaning. Alternatively, an item might 'behave poorly' because the symptom described is very rare. In either case, we suggest that researchers do not stop tool development work when internal consistency was detected as insufficient in a first validation study, because additional validation work superimposed on a tool with poor reliability has no promise.
In summary, at this time there exists a reasonable selection of brief tools with good psychometrics that are suitable for both daily clinical use and for research. We do not encourage the development of additional measures unless they have a truly innovative application. On the other hand, there are good reasons and opportunities for trying to further improve some existing, highly rated measures.
